The field of antibody-drug conjugates (ADC) has seen an explosive growth during the last few years. The number of ADC companies evaluated for preparation of the present report was nearly triple that described in the previous edition of the ADC report in the year 2011. For more information visit: http://goo.gl/gqRRR4

1. Category : Pharma and Healthcare
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com

2. Introduction to Report
 Launch Date: January 19, 2014
 Number of Pages: 347
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 2,873
Price For Site License: USD 5,746
Price For Global User License: USD 8,620
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com

3. About the Report
The report analyzes established and new
antibody-drug conjugate (ADC) technologies,
business activities and opportunities and
assesses more than 100 ADC development and
research programs.
The field of antibody-drug conjugates (ADC) has
seen an explosive growth during the last few
years. The number of ADC companies evaluated
for preparation of the present report was nearly
triple that described in the previous edition of
the ADC report in the year 2011.
www.MarketResearchReports.com

4. Research Findings
The report includes in the Addendum a tabulated
Competitor Analysis and lists all relevant business
transactions of the last two to three years.
Spefically, the ADC pipeline analysis describes preclinical,
non-clinical and clinical ADC projects and R&D programs.
It evaluates the ADC targets in relation to drug and linker
systems, and also investigates the clinical success and
reasons for failures of antibody-drug conjugates.
As a result of this conjugation technology, the drugantibody ratio may be variable and the product
heterogeneous with potential impact on efficacy, safety
and pharmacokinetics.
www.MarketResearchReports.com

5. Research Findings Continues..
Resistance of cancer cells to currently employed drug
payloads of ADCs adds a further parameter for
optimization of ADCs. Based on the current state of the
art, this report describes the emerging next generation
ADC technologies regarding target selection, novel
antibody and alternative targeting moiety formats, novel
drugs and conjugation systems. The report pays special
attention to the commercial relevance and value of these
technologies and highlights those picked-up by Big
Pharma setting a trend for the first wave of new ADCs
based on next generation ADC technologies.
www.MarketResearchReports.com

6. Research Findings Continues..
An Addendum lists ADC projects categorized by various
variablers and business agreements for collaborations,
licensing deals and M&A. Scientific references are
provided and non-scientific sources of information are
disclosed with hyperlinks.
Interestingly, Seattle Genetics abandoned its first
generation ADC against CD70 (SGN-75) based on MMAF
with a non-cleavable linker in phase I in favor of a next
generation ADC with PBD as drug.
www.MarketResearchReports.com

7. Benefits Of The Report:
Investors
Business developers
Licensing managers
Technology officers
R&D Management
Business & Competitive Intelligence Analysts
Scientific Analysts
R&D Planning
Portfolio Managers
www.MarketResearchReports.com

8. Find in The Report
Company profiles of ADC stakeholders
ADC drug profiles
ADC business agreements
ADC pipeline description and analysis
Clinical attrition rate of ADCs and reasons for failure
ADC target description and analysis
Current and future drugs, linkers and conjugation
systems
Industry preferences for drugs and linkers
Alternative targeting moieties
New uses of ADCs and immunoconjugates
CMOs for manufacturing of ADCs
Competitors
in
development,
technology
or
manufacturing
Commercial value of ADC products and technologies
www.MarketResearchReports.com

9. Report Coverage
1. Executive Summary
2. Introduction and Overview of the Report
3. Antibody-Drug Conjugates: Pipeline
Description and Analysis
4. Stakeholders in Antibody-Drug Conjugates
and Immunoconjugates
5. ADC Technologies
6. Business with Antibody-Drug Conjugates
7. ADC & Immunoconjugate Company Profiles
8. References
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com

10. Company Coverage (Partial List)
For more details regarding company coverage and TOC see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com

11. Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
www.MarketResearchReports.com

12. How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://www.marketresearchreports.com/la-meriepublishing/antibody-drug-conjugates-2014%E2%80%93-business-technology-pipeline-analysis
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)
www.MarketResearchReports.com